Clinical Trial: Clinical Usefulness of Optical Skin Biopsy
This study is currently recruiting patients.
Verified by National Taiwan University Hospital January 2004
| Sponsors and Collaborators: | National Taiwan University Hospital National Science Council, Taiwan National Health Research Instiutes, Taiwan | | Information provided by: | National Taiwan University Hospital | | ClinicalTrials.gov Identifier: | NCT00154921 | |
Purpose
Traditional
biopsy requires the removal, fixation, and staining of tissues from the human body. Its procedure is invasive and painful. Non-invasive
in vivo optical
biopsy is thus required, which should provide non-invasive, highly penetrative, three-dimensional (3D)
imaging with sub-micron spatial resolution. Optical
biopsy based on scanning two-photon fluorescence microscopy (TPFM) is a good method for
biopsy of skin due to its high lateral resolution, low out-of-focus damage, and intrinsic three-dimensional (3D) section capability. However current technology still presents several limitations including low penetration depth, in-focus
cell damages, and multi-photon phototoxicity due to high optical intensity in the 800 nm wavelength region, and toxicity if exogenous fluorescence markers were required. We study the harmonics optical
biopsy of a human skin sample using a femtosecond Cr:forsterite
laser cenetered at 1230 nm. Higher harmonics generation is known to leave no energy deposition to the interacted matters due to their energy-conservation characteristic. This energy-conservation characteristic provides the “noninvasive” nature desirable for
clinical imaging. In our study, we will evaluate the
clinical applications of optical skin
biopsy using harmonic generation microscopy.
| Condition | Phase |
Skin Neoplasms
| Phase I
|
MedlinePlus related topics: Skin Cancer
Study Type: Observational
Study Design: Natural History, Cross-Sectional, Defined Population, Retrospective/Prospective Study
Further Study Details:
Expected Total Enrollment: 30
Study start: January 2004; Expected completion: February 2008
Last follow-up: December 2007; Data entry closure: January 2008
Traditional
biopsy requires the removal, fixation, and staining of tissues from the human body. Its procedure is invasive and painful. Non-invasive
in vivo optical
biopsy is thus required, which should provide non-invasive, highly penetrative, three-dimensional (3D)
imaging with sub-micron spatial resolution. Optical
biopsy based on scanning two-photon fluorescence microscopy (TPFM) is a good method for
biopsy of skin due to its high lateral resolution, low out-of-focus damage, and intrinsic three-dimensional (3D) section capability. However current technology still presents several limitations including low penetration depth, in-focus
cell damages, and multi-photon phototoxicity due to high optical intensity in the 800 nm wavelength region, and toxicity if exogenous fluorescence markers were required. We study the harmonics optical
biopsy of a human skin sample using a femtosecond Cr:forsterite
laser cenetered at 1230 nm. Higher harmonics generation is known to leave no energy deposition to the interacted matters due to their energy-conservation characteristic. This energy-conservation characteristic provides the “noninvasive” nature desirable for
clinical imaging. In our study, we will evaluate the
clinical applications of optical skin
biopsy using harmonic generation microscopy.
Eligibility
Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Skin lesions admitted for surgical resection.
Exclusion Criteria:
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00154921
Wen-jeng Lee, M.D. jacklee@ntumc.org
Taiwan National Taiwan University Hospital, Taipei, 100, Taiwan; Recruiting
Wen-jeng Lee, M.D.
Study chairs or principal investigators
Wen-jeng Lee, M.D., Study Director, National Taiwan University Hospital
More Information
Study ID Numbers: 9361700212; NTUH-94M29
Last Updated: September 9, 2005
Record first received: September 9, 2005
ClinicalTrials.gov Identifier: NCT00154921
Health Authority: Taiwan: Department of Health
ClinicalTrials.gov processed this record on 2005-09-13
Source: ClinicalTrials.gov
Cache Date: September 14, 2005
Resources
- Kidney Biopsy (National Institute of Diabetes and Digestive and Kidney Diseases)